This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Bing Zhao, Sha Xu, Shiqing Zhou, Xiangru Jiang, Ailin Jiang, Hongrui Lei, Xin Zhai Bioorganic Chemistry, 163, 2025, 108800, [link] [link] the past two decades, covalent inhibitors have undergone a remarkable resurgence in drug discovery. Currently, targeting non-catalytic cysteine residues with acrylamide and other α,β-unsaturated carbonyl compounds is a predominate strategy, especially in the protein kinase field.
A gene is the essential hereditary unit that passes traits from parents to offspring; a segment of DNA containing instructions for making a specific protein or molecule that performs a particular function in your body. And yet, despite being fundamental to our flourishing, genes can be broken. Researchers have identified nearly 10,000 monogenic diseases , or conditions caused by errors in a single gene.
A groundbreaking study has revealed that the mass administration of ivermectin—a drug once known for treating river blindness and scabies—can significantly reduce malaria transmission when used in conjunction with bed nets.
When discussing how newer AI technologies like large language models (LLMs) could contribute to toxicity prediction, Hosseini-Gerami identified two key applications: 1. Improved scientist–data interaction: “Once we have all these datasets, have run these algorithms and have some outcomes and outputs, how can a scientist really engage with that information and use it to make a decision on what to do next?
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Antibody-drug conjugates (ADCs) are among the most exciting advances in target cancer therapy. They combine the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs to focus treatment on malignant cells while reducing damage to healthy cells.
A drug repurposing strategy was applied against M. abscessus, through a virtual screening of FDA approved drugs on salicylate synthase. Eleven potential ligands were found; among these, three were confirmed as potent inhibitors of the enzyme. ABSTRACT Non-tuberculous mycobacteria (NTM) are opportunistic pathogens that lead to severe, persistent infections, particularly in immunocompromised or vulnerable individuals.
More Information, Same Enrollment Challenges In clinical trial feasibility, we face a counterintuitive reality: despite unprecedented access to healthcare professional data, identifying the right investigators and predicting enrollment success has become increasingly challenging. This paradox, highlighted in a recent Life Sciences DNA podcast featuring Ariel Katz, co-founder and CEO of H1, in conversation with Dr.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
More Information, Same Enrollment Challenges In clinical trial feasibility, we face a counterintuitive reality: despite unprecedented access to healthcare professional data, identifying the right investigators and predicting enrollment success has become increasingly challenging. This paradox, highlighted in a recent Life Sciences DNA podcast featuring Ariel Katz, co-founder and CEO of H1, in conversation with Dr.
Biopharma and biotech industries are facing remarkable challenges as the cost of developing new drugs has surged dramatically and clinical trial timelines have extended significantly. For example, over the past decade, the average time required to complete a clinical trial has increased by approximately 20-30%. These elongated timelines are contributing to soaring costs, with the average cost of developing a new drug rising to approximately $2.6 billion (versus $1-1.5 billion just a decade ago).
Uncovering the Secret Formulas: How Drug Patents Reveal the Competition's Playbook As the pharmaceutical industry continues to evolve, companies are under increasing pressure to innovate and stay ahead of the curve. But what if the key to unlocking your competitors' strategies lies in plain sight – hidden in the complex web of drug patents? A new analysis from Drug Patent Watch reveals the surprising ways in which competitors are using patent data to inform their formulation strategies.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
This blog post was written by Dr. Kutubuddin Molla, investigator at ICAR-Central National Rice Research Institute. When it comes to genome editing, CRISPR is a name that resonates with nearly every biologist, academic, and researcher. Among the most well-known CRISPR-associated nucleases are Cas9 and Cas12a, the heavyweights in the genome editing toolbox.
By John A. Gilbert & Karla L. Palmer & Larry K. Houck & Andrew J. Hull — Last week, DEA registrants and applicants with pending actions before DEA’s Office of Administrative Law Judges (OALJ) received an order from Chief Administrative Law Judge John J. Mulrooney, II, staying the hearing proceedings in those cases. In those orders, Chief Judge Mulrooney announced that he was retiring from the bench effective August 1, 2025, and that, in the absence of any other DEA ALJs, all proceed
Skip to main content Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.
Effective financial management is a cornerstone in the success of clinical trials, which are integral to the advancement of drug discovery. As the pharmaceutical and biotech industries continue to evolve, clinical trials become more complex, and the importance of robust financial oversight has never been clearer. Jennifer Kyle, Founder and CEO of Condor Software, has witnessed these challenges first-hand and developed a solution aimed at bridging the gap between financial management and clinical
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmacovigilance is a global responsibility, and regulatory requirements may differ significantly depending on the region. One such region-specific requirement is the Periodic Adverse Drug Experience Report (PADER) , a post-marketing safety report mandated by the U.S. Food and Drug Administration (FDA). While many in the pharmaceutical industry may already be familiar with the Periodic Safety Update Report (PSUR) , which we previously covered on our website, understanding how PADER differs from
How Science Can Drive Better Business Decisions in Biopharma A scientific approach to decision-making can improve clinical development, as well as corporate, portfolio, & product strategy. Here’s a framework. jpiatt Tue, 07/29/2025 - 09:28 A scientific approach to decision-making can improve clinical development, as well as corporate, portfolio, & product strategy.
A pioneering team at the University of Maryland has captured the first-ever images of atomic thermal vibrations, unlocking an unseen world of motion within two-dimensional materials. Their innovative electron ptychography technique revealed elusive “moiré phasons,” a long-theorized phenomenon that governs heat, electronic behavior, and structural order at the atomic level.
MONDAY, July 28, 2025 — More than 2.5 million deaths were prevented worldwide by the cutting-edge vaccines developed for COVID-19, mainly among seniors, a new analysis says. Essentially, one death was averted for every 5,400 doses.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Disruption in the Lab: Why Business Continuity Planning is a Lifeline for Biomedical Research As the life sciences industry grapples with unprecedented disruptions, from supply chain shortages to global pandemics, biomedical and research organizations are facing unprecedented challenges to their very existence. In our latest report, we explore the critical importance of business continuity and resiliency planning for these organizations, and why it's no longer a nicety, but a necessity.
Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its competition with rival Eli Lilly.
Penn State researchers have uncovered a surprising twist in a foundational chemical reaction known as oxidative addition. Typically believed to involve transition metals donating electrons to organic compounds, the team discovered an alternate path—one in which electrons instead move from the organic molecule to the metal. This reversal, demonstrated using platinum and palladium exposed to hydrogen gas, could mean chemists have misunderstood a fundamental step for decades.
MONDAY, July 28, 2025 — Parkinson’s disease can dramatically affect a patient’s ability to walk, with “Parkinson’s gait” increasing their fall risk and reducing their ability to get around. But deep brain.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
President Donald Trump and European Commission President Ursula von der Leyen appear to differ on how their trade agreement addresses pharma-specific tariffs.
Advanced assay drug development technologies are increasingly used to evaluate cytotoxicity, enabling more efficient and accurate drug development. This article focuses on cytotoxicity assays. However, these are often combined with viability tests for normalization purposes.
"Unlocking the Secret to Market Supremacy: How to Own a Market You Don't Own As the pharmaceutical industry continues to evolve, one thing remains constant: the pursuit of market dominance. But what if you're not the first to market? What if your competitor has already established a stronghold on the market? In our latest report, we reveal the strategies that top pharmaceutical companies are using to gain market access and own a market they don't own.
MONDAY, July 28, 2025 — Cutting-edge immunotherapy drugs are incredibly effective against some cancers but barely put a dent in others – and researchers might now know why. Patients’ own autoantibodies – immune proteins.
Scientists at OIST have defied a foundational rule in chemistry by creating a stable 20-electron version of ferrocene—an organometallic molecule once thought to be limited to 18 valence electrons. This discovery not only challenges conventional wisdom but unlocks new chemical behaviors and redox states, potentially transforming how catalysts and materials are designed.
Skip to main content Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.
Running a Sitecore Docker instance is a game-changer for developers. It streamlines deployments, accelerates local setup, and ensures consistency across environments. However, performance can suffer – even on high-end laptops – if Docker resources aren’t properly optimized, especially after a hardware upgrade. I recently faced this exact issue.
TUESDAY, July 29, 2026 — Artificial intelligence (AI) may be guiding doctors towards a gut-focused means of accurately diagnosing chronic fatigue syndrome (CFS), new research shows.The illness appears to disrupt relationships between a person’s gut.
Deep beneath the Swiss-French border, the Large Hadron Collider unleashes staggering amounts of energy and radiation—enough to fry most electronics. Enter a team of Columbia engineers, who built ultra-rugged, radiation-resistant chips that now play a pivotal role in capturing data from subatomic particle collisions. These custom-designed ADCs not only survive the hostile environment inside CERN but also help filter and digitize the most critical collision events, enabling physicists to study elu
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content